Verastem reports VS-7375 clears first two doses with tumor reduction in 4/5 evaluable patients

Verastem, Inc.

No DLTs at 400 mg QD and 600 mg QD; no nausea/vomiting/diarrhea > Grade 1.
4 of 5 efficacy-evaluable patients had tumor reduction and remain on treatment.
Enrollment started for VS-7375 + cetuximab combo cohort in advanced solid tumors.
Interim safety/efficacy update expected in first half 2026.
Monotherapy dose escalation continues to 900 mg QD to select recommended Phase 2 dose.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.